Clinical efficacy of remdesivir for COVID-19 in children: A propensity-score-matched analysis.
Children
Coronavirus disease 2019
Defervescence
Remdesivir
Severe acute respiratory syndrome coronavirus 2
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
07
05
2023
revised:
01
06
2023
accepted:
06
06
2023
medline:
2
8
2023
pubmed:
15
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Clinical efficacy of remdesivir in children with COVID-19 is unclear. This propensity-score-matched retrospective cohort study of children with COVID-19 showed that the rate of patients achieving defervescence on Day 4 was higher in the remdesivir group than in the non-remdesivir group, but was not statistically different (86.7% vs 73.3%, P = 0.333).
Identifiants
pubmed: 37315843
pii: S1341-321X(23)00149-6
doi: 10.1016/j.jiac.2023.06.006
pmc: PMC10259089
pii:
doi:
Substances chimiques
Antiviral Agents
0
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
930-933Informations de copyright
Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest K. Shoji received payment for lectures from bioMérieux Japan, Nippon Becton Dickinson Company, Ltd., Viatris, Inc., Meiji Seika Pharma Co., Ltd., AstraZeneca K.K., Novartis Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Gilead Sciences, Inc. S. Tsuzuki received payment for supervising medical articles from Gilead Sciences, Inc. I. Miyairi received payment for lectures from Astellas Pharma, Sanofi K.K., Pfizer, Inc., Takeda Pharmaceutical Company, Ltd., Biken Group, Shionogi & Company, Ltd., bioMérieux Japan, and Gilead Sciences, Inc. The other authors declare that they do not have any conflicts of interests directly associated with the study.